Rehmann Capital Advisory Group’s United Therapeutics UTHR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Sell	2,957 -662	-18%	-$330K	0.09%	159
2025 Q4	$1.77M	Buy	3,619 +324	+10%	+$151K	0.09%	153
2025 Q3	$1.38M	Buy	3,295 +1,125	+52%	+$378K	0.08%	176
2025 Q2	$624K	Buy	2,170 +348	+19%	+$104K	0.04%	308
2025 Q1	$562K	Buy	+1,822	New	+$624K	0.04%	332
2019 Q3	$3.11K	Hold	39	–	–	﹤0.01%	1324
2019 Q2	$3.04K	Hold	39	–	–	﹤0.01%	1680
2019 Q1	$4.58K	Hold	39	–	–	﹤0.01%	1553
2018 Q4	$4.25K	Hold	39	–	–	﹤0.01%	1297
2018 Q3	$4.99K	Sell	39 -80	-67%	-$9.89K	﹤0.01%	1561
2018 Q2	$13.5K	Hold	119	–	–	﹤0.01%	1241
2018 Q1	$13K	Buy	+119	New	+$15.1K	﹤0.01%	1224
2014 Q4	–	Sell	-1,610	Closed	-$207K	–	358
2014 Q3	$207K	Buy	+1,610	New	+$166K	0.05%	307
2014 Q1	–	Sell	-2,671	Closed	-$302K	–	346
2013 Q4	$302K	Buy	+2,671	New	+$241K	0.09%	203

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rehmann Capital Advisory Group's UTHR Position: Q1 2026 in Review

Rehmann Capital Advisory Group reduced its United Therapeutics (UTHR) stake by 18% in Q1 2026, selling an estimated $330K and leaving 2,957 shares worth $1.75M. The position accounts for 0.09% of the portfolio, ranked #159.

Rehmann Capital Advisory Group first reported a position in UTHR in Q4 2013 and has held it in 14 quarters since. The position peaked at $1.77M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Rehmann Capital Advisory Group held 2,957 shares of United Therapeutics worth $1.75M as of Q1 2026.
Rehmann Capital Advisory Group sold 662 United Therapeutics shares in Q1 2026, an estimated $330K.
United Therapeutics made up 0.09% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #159 holding.
Rehmann Capital Advisory Group first reported a position in United Therapeutics in Q4 2013 and has held it in 14 quarters since.
Rehmann Capital Advisory Group's United Therapeutics position peaked at $1.77M in Q4 2025.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.